245 related articles for article (PubMed ID: 31231022)
1. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
2. Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance.
Castro-Pérez E; Singh M; Sadangi S; Mela-Sánchez C; Setaluri V
Pigment Cell Melanoma Res; 2023 Sep; 36(5):330-347. PubMed ID: 37132530
[TBL] [Abstract][Full Text] [Related]
3. Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.
Granados K; Poelchen J; Novak D; Utikal J
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167306
[TBL] [Abstract][Full Text] [Related]
4. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.
Knappe N; Novak D; Weina K; Bernhardt M; Reith M; Larribere L; Hölzel M; Tüting T; Gebhardt C; Umansky V; Utikal J
Stem Cells; 2016 Apr; 34(4):832-46. PubMed ID: 26753613
[TBL] [Abstract][Full Text] [Related]
5. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response.
Bernhardt M; Novak D; Assenov Y; Orouji E; Knappe N; Weina K; Reith M; Larribere L; Gebhardt C; Plass C; Umansky V; Utikal J
Stem Cell Reports; 2017 May; 8(5):1379-1391. PubMed ID: 28392221
[TBL] [Abstract][Full Text] [Related]
7. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
Wessely A; Steeb T; Berking C; Heppt MV
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
[TBL] [Abstract][Full Text] [Related]
8. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
9. Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype.
Hiew MSY; Cheng HP; Huang CJ; Chong KY; Cheong SK; Choo KB; Kamarul T
J Biomed Sci; 2018 Jul; 25(1):57. PubMed ID: 30025541
[TBL] [Abstract][Full Text] [Related]
10. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
11. De- and re-differentiation of the melanocytic lineage.
Larribere L; Utikal J
Eur J Cell Biol; 2014; 93(1-2):30-5. PubMed ID: 24365127
[TBL] [Abstract][Full Text] [Related]
12. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.
Zecena H; Tveit D; Wang Z; Farhat A; Panchal P; Liu J; Singh SJ; Sanghera A; Bainiwal A; Teo SY; Meyskens FL; Liu-Smith F; Filipp FV
BMC Syst Biol; 2018 Apr; 12(1):33. PubMed ID: 29615030
[TBL] [Abstract][Full Text] [Related]
13. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
14. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
Granados K; Hüser L; Federico A; Sachindra S; Wolff G; Hielscher T; Novak D; Madrigal-Gamboa V; Sun Q; Vierthaler M; Larribère L; Umansky V; Utikal J
Br J Cancer; 2020 Mar; 122(7):1023-1036. PubMed ID: 32063604
[TBL] [Abstract][Full Text] [Related]
15. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
16. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
17. Linking Pluripotency Reprogramming and Cancer.
Iglesias JM; Gumuzio J; Martin AG
Stem Cells Transl Med; 2017 Feb; 6(2):335-339. PubMed ID: 28191771
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells and human malignant melanoma.
Schatton T; Frank MH
Pigment Cell Melanoma Res; 2008 Feb; 21(1):39-55. PubMed ID: 18353142
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
20. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
